University of Montréal
Collaborator: Dr. Keith Barrington, University of Montréal
Health Categories: Immunity
Research Summary: Neonatal sepsis is a worldwide public health problem, with higher incidence in the developing world. Despite advances in diagnosis and treatment, infections in the neonatal period remain a major cause of death in newborns. Lactoferrin (LF), a milk glycoprotein with anti-inflammatory, immunomodulatory and antimicrobial properties, has the potential to prevent infections in young children. Dr. Keith Barrington, and his team, performed a Phase II clinical trial in neonates with AOR providing the clinical trial material.
SF Summarization: This study tested the effects of Lactoferrin, a milk glycoprotein with anti-inflammatory, immunomodulatory and antimicrobial properties, as a treatment for neonatal sepsis.
Current Status: Completed
Stage: Clinical study